Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

owth and future development of the company, future acquisitions or dispositions of assets and guidance with respect to expected results of operation. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the company's ability to realize the benefits of its strategic restructuring plan, market conditions and other factors that may influence the company's determination as to whether and when to repurchase its securities, the ability of the company to complete the programs in compliance with applicable requirements, and other risks and uncertainties discussed in the company's annual report on Form 10-K for the year ended December 31, 2007 and other filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

Non-GAAP Information:

To supplement the consolidated financial results prepared in accordance with generally accepted accounting principles (GAAP), the company uses non- GAAP financial measures that exclude certain items, such as in-process research and development, restructuring, amortization, gain on early extinguishment of debt, and certain taxes. Management does not consider the excluded items part of day-to-day business or r
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 ... penis sometimes comes into contact with the dirty water ... or the seat itself," said one of two inventors ... exposure to germs, we developed this protective device." , ... contacting unsanitary toilet surfaces, including the water, bowl and ...
(Date:8/23/2014)... On Monday, August 18th, The New ... suffered by Community Health Systems, which operates over 200 ... records containing Personally Identifiable Information (PII) like names, phone ... was engaged to investigate the incident, the belief is ... cyber attackers based in China, who they say are ...
(Date:8/23/2014)... California (PRWEB) August 23, 2014 Pixel Film ... themes, announced today the release of ProIntro Vol.3, a customizable ... a fresh and professional tile just by dragging ProIntro Vol.3 ... Studios. "ProIntro Vol.3 is a definite time saver and i ... intro pack with 30 beautifully designed titles made with Final ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen ... North Carolina. It’s no different in Wilmington, NC. Substance ... adults are falling victim to drug and alcohol dependency ... people are looking to overcome substance abuse, but don’t ... an adolescent treatment facility can be a challenge because ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a ... years. He has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ... 2014. , GoDaddy is a popular supplier of cheap ... hosting solutions at affordable rates. It offers three Linux ... plans depend on the length of the contract. The ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... life for those with tumors in bile duct, gall bladder ... chemotherapy drug to the treatment regimen of people with biliary ... research. , This type of cancer -- which occurs in ... to treat and often fatal. , "These are uncommon ...
... failed, trial results show , WEDNESDAY, April 7 (HealthDay ... second-round treatment for hepatitis cures about half the people ... research shows. , "This is the first large study ... said Dr. John G. McHutchison, associate director of the ...
... ... pre-event for the American Cancer Society’s highly anticipated “Starry Night Gala” that will occur ... ... 7, 2010 -- “An Evening of Hope” is the official pre-event for the ...
... ... ... with alarming new statistics and some hopeful highlights too. The bad news: according to the ... States will be diagnosed with autism spectrum disorder, or ASD. That’s up dramatically from ...
... sexually transmitted diseases , WEDNESDAY, April 7 (HealthDay News) ... to have multiple partners, researchers have found, and that ... they note. , "The United States has seen a ... sexually involved when they are just casually dating or ...
... Researchers from Boston University School of Medicine (BUSM) ... have discovered a new approach for identifying smokers at ... which appear in the April 7th issue of ... use a genomic approach to prevent lung cancer in ...
Cached Medicine News:Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 2Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 3Health News:New Drug Shows Promise for Curing Hepatitis C 2Health News:New Drug Shows Promise for Curing Hepatitis C 3Health News:"An Evening of Hope” - The Official Pre-Event for This Year's American Cancer Society Starry Night Gala 2Health News:Increase in Autism Rate and Treatments Focus of Autism Awareness Month 2Health News:Casual Sex Increasing in U.S. 2Health News:Researchers discover new approach for identifying smokers at highest risk for developing lung cancer 2
(Date:8/22/2014)... , Aug. 22, 2014 MC Medical, a ... (MID), a Columbus, OH medical device ... the FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan in ... long-time experience and an extensive product portfolio in endoscopic surgery ...
(Date:8/22/2014)... 22, 2014  Mark Riccio, director of Cornell ... is using the online crowd-funding platform Kickstarter to ... to researchers and would-be superheros everywhere: "for FREE." ... YOU do if you had Superman,s X-ray vision?" ... explorers everywhere, from elementary through high school students, ...
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Republic, November 10, 2010, ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Nov. 10, 2010 A new initiative launched ... www.icsi.org ), a nonprofit, health care improvement ... more than $28 million annually, as well as ... The initiative is the first statewide diagnostic ...
Cached Medicine Technology:Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 2Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 3Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 4Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 5Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 6Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 7Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 8Novasep and Mega Sign a Strategic Technology Partnership to Develop Whey Treatment Solutions for the Dairy Industry 9Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 2Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 3Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 4Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 5
... HCS INTERACTANT is ... system. Financial applications include ... human resources and comprehensive ... financial applications are designed ...
... (Nitrogen) powder reagent once reconstituted offers the ... stability to help maximize laboratory productivity, minimize ... time. The patented technology of the Infinity ... shelf life and stability once reconstituted that ...
... The Infinity Triglycerides single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Triglycerides reagent provides a ...
... Creatinine single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... reagent provides a long shelf life ...
Medicine Products: